| Test-Retest, Responsiveness, and Minimal Important Change of the Ability to Perform Physical Activities of Daily Living Questionnaire in Individuals with Type 2 Diabetes and Obesity. | |
| | |
MedLine Citation:
|
PMID: 23016515 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Abstract Background: The Ability to Perform Physical Activities of Daily Living Questionnaire (APPADL) measures the self-reported ability of individuals with type 2 diabetes mellitus (T2DM) and obesity to perform daily physical activities. The primary objective of this study was to estimate APPADL test-retest reliability, responsiveness, and minimal important change (MIC). Subjects and Methods: Study participants were individuals with T2DM and body mass index ≥30 kg/m(2) enrolled in clinical weight loss programs in the United States. Data were obtained for clinical measures, APPADL, and other patient-reported instruments. APPADL test-retest reliability was estimated with intraclass correlation coefficient. To estimate responsiveness in a subgroup of participants, baseline and 6-month data were analyzed using paired t test and calculation of responsiveness indices (e.g., effect size [ES]). To estimate MIC, both distribution-based and anchor-based methods were used. Results: Test-retest data for 106 study participants (mean age, 52 years; 69% female; 31% white; mean body mass index, 38 kg/m(2)) yielded an intraclass correlation coefficient of 0.91. In the subgroup (n=40) used to estimate responsiveness, weight was significantly less at end point than at baseline (mean, 222.0 vs. 231.9 pounds; P<0.001, ES=0.24), and APPADL scores were significantly better than at baseline (mean, 77.0 vs. 70.8; P=0.01, ES=0.32). Results of distribution- and anchor-based methods to establish MIC suggest values of 6-14 points (0-100 scale). Conclusions: The APPADL has demonstrated reliability and validity. In addition, it has demonstrated responsiveness to weight loss in individuals with T2DM and obesity, thereby making it a potentially valuable tool in the evaluation of weight loss interventions (e.g., antihyperglycemic medications that produce weight loss) targeted toward patients with T2DM. |
| | |
Authors:
|
Risa P Hayes; Elisabeth M Schultz; April N Naegeli; Bradley H Curtis |
Related Documents
:
|
23560465 - Development of the knowledge-based & empirical combined scoring algorithm (kecsa) to sc... 23353845 - Effect of four selected carrier solvents on embryonal stages of danio rerio. 23168375 - Evaluation of a specific reaction and action speed (ras) test for the soccer goalkeeper. 287325 - Diagnostic procedures in chronic rhinitis. 21468615 - The effect of prophylactic knee bracing on performance: balance, proprioception, coordi... 9358115 - Thespesia populnea dermatitis. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-9-27 |
Journal Detail:
|
Title: Diabetes technology & therapeutics Volume: - ISSN: 1557-8593 ISO Abbreviation: Diabetes Technol. Ther. Publication Date: 2012 Sep |
Date Detail:
|
Created Date: 2012-9-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100889084 Medline TA: Diabetes Technol Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
1 Global Health Outcomes, Eli Lilly and Company , Indianapolis, Indiana. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evidence for pathogenicity of autoreactive T cells in autoimmune bullous diseases shown by animal di...
Next Document: Sensor-Augmented Pump Therapy at 36 Months.